UGT1A1*1/*28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 279-284

  Sunakawa, Yu ^a   Ichikawa, Wataru ^a,b   Fujita, Ken Ichi ^a   Nagashima, Fumio ^a   Ishida, Hiroo ^a   Yamashita, Keishi ^a   Mizuno, Keiko ^a   Miwa, Keisuke ^a   Kawara, Kaori ^a   Akiyama, Yuko ^a   Araki, Kazuhiro ^a   Yamamoto, Wataru ^a   Miya, Toshimichi ^a   Narabayashi, Masaru ^a   Ando, Yuichi ^a   Hirose, Takashi ^a   Saji, Shigehira ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Efficacy; Heterozygote; Irinotecan; Toxicity; UGT1A1*28; UGT1A1*6

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; PRODRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GENE; GENOTYPE; HUMAN; INFECTION; JAPANESE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UDP GLUCURONOSYLTRANSFERASE 1A1 GENE; ALLELE; BIOTRANSFORMATION; CANCER STAGING; COLORECTAL TUMOR; ENZYMOLOGY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; JAPAN; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HUMANS; JAPAN; LEUCOVORIN; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PRODRUGS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOPOISOMERASE I INHIBITORS;

EID: 79959750597     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1485-8     Document Type: Article

References (18)

1. RHJ Mathijssen RJ van Alphen J Verweij WJ Loos K Nooter G Stoter A Sparreboom 2001 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2182 2194 11489791 1:CAS:528:DC%2BD3MXmsVOmsbg%3D (Pubitemid 32751614)
2. F Innocenti SD Undevia L Iyer P Xian Chen S Das M Kocherginsky T Karrison L Janisch J Ramirez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388 15007088 10.1200/JCO.2004.07.173 1:CAS:528:DC%2BD2cXpt1yjtbk%3D (Pubitemid 41103619)
3. Y Ando H Saka M Ando T Sawa K Muro H Ueoka A Yokoyama S Saitoh K Shimokata Y Hasegawa 2000 Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921 6926 11156391 1:CAS:528:DC%2BD3MXjsVOjsA%3D%3D (Pubitemid 32059164)
4. E Beutler T Gelbart A Demina 1998 Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95 8170 8174 9653159 10.1073/pnas.95.14.8170 1:CAS:528:DyaK1cXks1Skur4%3D (Pubitemid 28326085)
5. JF Gagne V Montminy P Belanger K Journault G Gaucher C Guillemette 2002 Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) Mol Pharmacol 62 608 617 12181437 10.1124/mol.62.3.608 1:CAS:528:DC%2BD38XmsVKmuro%3D (Pubitemid 36329379)
6. Y Akiyama K Fujita F Nagashima W Yamamoto H Endo Y Sunakawa K Yamashita H Ishida K Mizuno K Araki W Ichikawa T Miya M Narabayashi K Kawara M Sugiyama T Hirose Y Ando Y Sasaki 2008 Genetic testing for UGT1A1*28 and*6 in Japanese patients who receive irinotecan chemotherapy Ann Oncol 19 2089 2090 18953066 10.1093/annonc/mdn645 1:STN:280:DC%2BD1cjlsl2jtQ%3D%3D
7. H Minami K Sai M Saeki Y Saito S Ozawa K Suzuki N Kaniwa J Sawada T Hamaguchi N Yamamoto K Shirao Y Yamada H Ohmatsu K Kubota T Yoshida A Ohtsu N Saijo 2007 Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28 Pharmacogenet Genomics 17 497 504 17558305 10.1097/FPC.0b013e328014341f 1:CAS:528: DC%2BD2sXmtlShs7k%3D (Pubitemid 46905216)
8. J-Y Han H-S Lim ES Shin Y-K Yoo YH Park J-E Lee I-J Jang D Ho Lee J Soo Lee 2006 Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin J Clin Oncol 24 2237 2244 16636344 10.1200/JCO.2005.03.0239 1:CAS:528:DC%2BD28XlvV2ksLg%3D (Pubitemid 46630652)
9. G Toffoli E Cecchin G Corona A Russo A Buonadonna M D'Andrea LM Pasetto S Pessa D Errante V De Pangher M Giusto M Medici F Gaion P Sandri E Galligioni S Bonura M Boccalon P Biason S Frustaci 2006 The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer J Clin Oncol 24 3061 3068 16809730 10.1200/JCO.2005.05.5400 1:CAS:528:DC%2BD28XnslKhs7w%3D (Pubitemid 46638941)
10. JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 10744089 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D (Pubitemid 30162806)
11. C Tournigand T Andre E Achille G Lledo M Flesh D Mery-Mignard E Quinaux C Couteau M Buyse G Ganem B Landi P Colin C Louvet A de Gramont 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 14657227 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
12. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
13. K Fujita Y Ando F Nagashima W Yamamoto H Eodo K Araki K Kodama T Miya M Narabayashi Y Sasaki H Endo M Ando Y Hasegawa Y Sekido K Shimokata H Ueoka T Sugiyama M Ichiki H Saka T Sawa K Muro A Yokoyama S Saitoh 2007 Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer Cancer Chemother Pharmacol 60 515 522 17406868 10.1007/s00280-006-0396-1 1:CAS:528:DC%2BD2sXnvFKnsb0%3D (Pubitemid 47084262)
14. E Marcuello A Altes A Menoyo E Del Rio M Gomez-Pardo M Baiget 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678 682 15280927 1:CAS:528:DC%2BD2cXmsVCgtr0%3D (Pubitemid 39141623)
15. E Cecchin F Innocenti M D'Andrea G Corona E De Mattia P Biason A Buonadonna G Toffoli 2009 Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J Clin Oncol 27 2457 2465 19364970 10.1200/JCO.2008.19.0314 1:CAS:528: DC%2BD1MXmvVOhsL0%3D
16. K Araki K Fujita Y Ando F Nagashima W Yamamoto H Endo T Miya K Kodama M Narabayashi Y Sasaki 2006 Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 1255 1259 16965601 10.1111/j.1349-7006.2006.00321.x 1:CAS:528:DC%2BD28XhtFemtbbN (Pubitemid 44430653)
17. JM Hoskins RM Goldberg P Qu JG Ibrahim HL McLeod 2007 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 1290 1295 17728214 10.1093/jnci/djm115 1:CAS:528:DC%2BD2sXhtVWqtbnI (Pubitemid 47394168)
18. W Ichikawa K Araki K Fujita W Yamamoto H Endo F Nagashima R Tanaka T Miya K Kodama Y Sunakawa M Narabayashi Y Ando Y Akiyama K Kawara Y Sasaki 2008 Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 100 224 225 18230796 10.1093/jnci/djm302 (Pubitemid 351480550)